HeartMate 3 CE Mark Trial 1-Year Results Presented at ISHLT 36th Annual Meeting and Scientific Sessions in Washington, D.C.
April 28, 2016 11:13 ET
|
International Society for Heart and Lung Transplantation
WASHINGTON, April 28, 2016 (GLOBE NEWSWIRE) -- At today's opening plenary session at the 36th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific Sessions,...
National Institutes of Health and Mesoblast Enter Into Agreement for 120-Patient Trial In End-Stage Heart Failure
August 06, 2014 20:57 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the signing of an agreement with the United...
Improved Outcomes Using Mesoblast Cells in End-Stage Heart Failure
June 24, 2014 21:19 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 24, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that trial results evaluating a low dose...
Mesoblast's Cell Therapy Strengthens Native Heart Function In Patients With End-Stage Heart Failure on Assisted Circulatory Support
November 18, 2013 18:14 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 18, 2013 (GLOBE NEWSWIRE) -- Patients with end-stage or New York Heart Association (NYHA) class IV heart failure who receive a surgically implanted left...
Sunshine Heart Announces Results of Its C-Pulse(R) Feasibility Trial at the Transcatheter Cardiovascular Therapeutics Conference
November 07, 2011 08:00 ET
|
Sunshine Heart, Inc.
SYDNEY, AUSTRALIA and EDEN PRAIRIE, MN--(Marketwire - Nov 7, 2011) - Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for moderate to severe heart...
Sunshine Heart's Feasibility Trial Outcomes to Be Presented at Transcatheter Cardiovascular Therapeutics Conference
October 19, 2011 05:00 ET
|
Sunshine Heart, Inc.
SYDNEY, AUSTRALIA and EDEN PRAIRIE, MN--(Marketwire - Oct 19, 2011) - Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for moderate heart failure,...
Sunshine Heart Appoints New US Board Member
August 03, 2011 15:19 ET
|
Sunshine Heart, Inc.
SYDNEY, AUSTRALIA and EDEN PRAIRIE, MN--(Marketwire - Aug 3, 2011) - Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for moderate heart failure,...
Sunshine Heart Completes Feasibility Study for Fully-Implantable C-Pulse(R) Heart Assist System
June 08, 2011 18:53 ET
|
Sunshine Heart, Inc.
MINNEAPOLIS, MN--(Marketwire - Jun 8, 2011) - Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for Class III/ambulatory Class IV (moderate to...
Sunshine Heart Receives Approval to Expand C-Pulse(R) Heart Assist System Study
April 10, 2011 19:00 ET
|
Sunshine Heart, Inc.
MINNEAPOLIS, MN--(Marketwire - Apr 10, 2011) - Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for Class III/ambulatory Class IV (moderate to...
Sunshine Heart Announces Completion of Enrollment of 20 Patients for C-Pulse(R) Heart Assist System
April 03, 2011 19:00 ET
|
Sunshine Heart, Inc.
MINNEAPOLIS, MN--(Marketwire - April 3, 2011) - Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for moderate to severe heart failure, today...